Latest News

Monday, July 27, 2015 | Acquisitions/Mergers, Allergan

Teva Deal Lets Us Double Down on Brands: Allergan CEO

Allergan President and CEO Brent Saunders said Monday the sale of its generics business would allow the company to double down on its higher margin, higher growth branded drugs business. Saunders spok…

Read the full story

Monday, July 27, 2015 | Product Releases

Opternative Launches Online, Ophthalmologist-Issued Prescription Service for Glasses and Contacts

Opternative has launched the first online eye exam service, which can provide consumers with a convenient and affordable physician-issued prescription for glasses or contacts, according to a company n…

Read the full story

Monday, July 27, 2015 | Acquisitions/Mergers, Allergan

Allergan to Acquire Naurex for $560 Million

Allergan and Naurex, a clinical-stage biopharmaceutical company developing transformative therapies for challenging disorders of the central nervous system, announced that they have entered into a def…

Read the full story

Monday, July 27, 2015 | Acquisitions/Mergers, Allergan

Teva to Acquire Allergan Generics for $40.5 Billion

Teva Pharmaceutical announced that it has signed a definitive agreement with Allergan to acquire Allergan's generics business in a transaction valued at $40.5 billion, according to a company news …

Read the full story

Friday, July 24, 2015 | Miscellaneous, Eyegate Pharmaceuticals

EyeGate Pharma Receives USPTO Notice of Allowance for Proprietary Dexamethasone Phosphate Formulation

Eyegate Pharmaceuticals announced that it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent application related to its lead product candidate, EGP-437. Th…

Read the full story

Friday, July 24, 2015 | Product Releases, Santen

Santen Launches Ikervis - The First and Only Ciclosporin Eye Drops Licensed in the UK

Santen UK Limited announced the launch of Ikervis (ciclosporin 1 mg/mL eye drops emulsion in single-dose containers) in the UK, according to a company news release. Ikervis is licensed for the…

Read the full story

Friday, July 24, 2015 | Retina

NICE Recommends Ozurdex for Pseudophakic Patients with DME

The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the dexamethasone intravitreal implant for the treatment of diabetic macular edema (DME).

Read the full story

Friday, July 24, 2015 | Management/Leadership, STAAR Surgical

Jon K. Hayashida Named Vice President Global Clinical and Medical Affairs for STAAR Surgical

STAAR Surgical has named Jon K. Hayashida, OD, to the newly created position of vice president of global clinical and medical affairs, according to a company news release. In this position, he will he…

Read the full story

Thursday, July 23, 2015 | Clinical Trials

Inotek Announces Positive End-of-Phase 2 Meeting with FDA and Phase 3 Development Strategy for Glaucoma Treatment Trabodenoson

Inotek Pharmaceuticals announced the phase 3 development strategy of its lead glaucoma drug, trabodenoson, a first-in-class selective adenosine mimetic designed to restore the eye’s natural pres…

Read the full story

Thursday, July 23, 2015 | Medical Studies

Squalamine Shows Promise in Retinal Vein Occlusion

Adding topical squalamine to ranibizumab (Lucentis, Genentech, Inc) improves visual acuity significantly more than ranibizumab alone in patients with retinal vein occlusion, a small trial shows. "…

Read the full story

Thursday, July 23, 2015 | Cataract Surgery

Is This The End of Cataract Operations? New Eye Drops Dissolve the Deposits That Cause Cloudy Vision

Eye drops that could replace cataract operations are being developed by doctors. Inexpensive to make and easy to administer, the twice-a-day drops could be in widespread use in as little as five years…

Read the full story

Wednesday, July 22, 2015 | Clinical Trials, Second Sight Medical Products

Second Sight Announces First AMD Patient Receives the Argus II Retinal Prosthesis System

Second Sight Medical Products announced the first implant and successful activation of the Argus II Retinal Prosthesis System in a dry age-related macular degeneration (AMD) patient, according to a co…

Read the full story

Wednesday, July 22, 2015 | Earnings & Financials

Xoma's Stock Plunges Below $1 After Trial Results Disappoint

Biotechnology company Xoma Corp.'s stock crashed 81% in premarket trade Wednesday, after the company said a late-stage trial of its treatment (gevokizumab) for Behcet's disease in the eye miss…

Read the full story

Wednesday, July 22, 2015 | Management/Leadership

Inotek Pharmaceuticals Appoints Dr. Cadmus Collins Rich as Vice President, Medical Affairs and Clinical Development

Inotek Pharmaceuticals announced the appointment of ophthalmic drug development expert, Cadmus Collins Rich, MD, MBA, CPE, as vice president, medical affairs and clinical development, according to a c…

Read the full story

Wednesday, July 22, 2015 | Medical Studies

Aspirin Benefits Outweigh Risks in Macular Degeneration

Patients can continue to take aspirin as recommended by their primary care physicians without fear of worsening their macular degeneration, researchers say. "Taking patients off aspirin can cause…

Read the full story
Load More
 Stock Price  Change 
 Actavis $298.98  0.00% 
 Aerie Pharmaceuticals, Inc. $18.55  0.00% 
 Akorn, Inc. $46.16  0.00% 
 Alimera Sciences, Inc. $4.56  0.00% 
 Avalanche Biotechnologies $14.29  0.00% 
 Bayer $141.48  0.00% 
 Can-Fite Biopharma $1.89  0.00% 
 Carl Zeiss Meditec $24.62  0.35% 
 Cooper Companies, Inc. $171.86  0.00% 
 Eleven Biotherapeutics $2.81  0.00% 
 Escalon Medical Corp. $1.35  0.00% 
 Essilor International $130.00  0.00% 
 Imprimis Pharmaceuticals, Inc. $8.10  0.00% 
 InSite Vision, Inc. $0.18  0.00% 
 IRIDEX Corporation $6.97  0.00% 
 Johnson & Johnson $98.28  0.00% 
 Luxottica Group, S.p.A. $70.60  0.00% 
 Merck & Company, Inc. $56.99  0.00% 
 NicOx $1.96  -0.10% 
 NovaBay Pharmaceuticals, Inc. $0.59  0.00% 
 Novartis AG Common Stock $101.54  0.00% 
 Ocular Therapeutix $25.48  0.00% 
 Ophthotech Corporation $66.42  0.00% 
 QLT $3.90  0.00% 
 Quantel $3.18  0.00% 
 Regeneron $540.03  0.00% 
 Roche $35.60  0.00% 
 Second Sight Medical Products $14.36  0.00% 
 STAAR Surgical Company $8.64  0.00% 
 TearLab Corporation $2.40  0.00% 
 Thrombogenics $5.39  0.00% 
 Topcon Corporation $22.55  0.00% 
 Valeant Pharmaceuticals $257.30  0.00% 
 Xoma $0.82  0.00%